Table 2.

Gastrointestinal-related treatment-emergent adverse events in humans after a single dose (a) or multiple ascending doses (b) of placebo and AMG 133

a
	Placebo (n = 12)	21 mg (n = 6)	70 mg (n = 6)	140 mg (n = 7)	280 mg (n = 6)	560 mg (n = 6)	840 mg (n = 6)
Number of individuals reporting TEAEs	3 (25.0)	0 (0.0)	2 (33.3)	5 (71.4)	6 (100.0)	5 (83.3)	6 (100.0)
GI disorders
Diarrhoea	2 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dyspepsia	1 (8.3)	0 (0.0)	1 (16.7)	4 (57.1)	0 (0.0)	0 (0.0)	0 (0.0)
Abdominal discomfort	0 (0.0)	0 (0.0)	0 (0.0)	2 (28.6)	0 (0.0)	0 (0.0)	0 (0.0)
Constipation	1 (8.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	3 (50.0)
Gastroesophageal reflux disease	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Nausea	3 (25.0)	0 (0.0)	2 (33.3)	4 (57.1)	4 (66.7)	5 (83.3)	5 (83.3)
Vomiting	0 (0.0)	0 (0.0)	1 (16.7)	4 (57.1)	5 (83.3)	5 (83.3)	4 (66.7)
GI safety laboratory
Amylase elevation	0 (0.0)	0 (0.0)	0 (0.0)	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)
Lipase elevation	0 (0.0)	0 (0.0)	0 (0.0)	1 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)
Hepatic enzyme elevation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)

b
	Placebo (n = 6)	140 mg (n = 6)	280 mg (n = 6)	420 mg (n = 8)
Number of individuals reporting TEAEs	3 (50.0)	6 (100.0)	6 (100.0)	8 (100.0)
GI disorders
Diarrhoea	0 (0.0)	1 (16.7)	0 (0.0)	2 (25.0)
Dyspepsia	0 (0.0)	1 (16.7)	0 (0.0)	1 (12.5)
Abdominal distension	0 (0.0)	1 (16.7)	0 (0.0)	1 (12.5)
Abdominal pain upper	0 (0.0)	0 (0.0)	0 (0.0)	1 (12.5)
Constipation	0 (0.0)	2 (33.3)	1 (16.7)	0 (0.0)
Nausea	1 (16.7)	5 (83.3)	4 (66.7)	8 (100.0)
Vomiting	0 (0.0)	4 (66.7)	5 (83.3)	6 (75.0)
GI safety laboratory
Amylase elevation	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)
Lipase elevation	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)

Data show number (%) of participants with the event of interest.